nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1352Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESО синергизме иммунодепрессивных препаратов. (Кемпас в комплексе индукционной иммунодепрессии)About synergism of immunosuppressants. (Kampath in complex of inductive immunosuppression)ГоряйновВ. А.GoriaynovV. A.noemail@neicon.ruКаабакМ. М.KaabakM. M.noemail@neicon.ruШишлоЛ. А.ShyshloL. A.noemail@neicon.ruГУ РНЦХ РАМН им. акад. Б.В. ПетровскогоRussian Federation20072306202592155158Copyright © Горяйнов В.А., Каабак М.М., Шишло Л.А., 20252025Горяйнов В.А., Каабак М.М., Шишло Л.А.Goriaynov V.A., Kaabak M.M., Shyshlo L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1352

С того момента как в комплекс иммунодепрессии в отделении трансплантации почки РНЦХ РАМН был введен Кемпас, мы решили выяснить способен ли он потенцировать действие вводимого параллельно Зенапакса. Для этого была оценена продолжительность интервала между введениями Зенапакса. Кемпас вводили 7 больным дважды: первое введение осуществляли за 18-21 дней до трансплантации, второе - в день пересадки сразу по окончании плазмафереза. В качестве контрольной группы взяты 9 больных, которым индукционную иммунодепрессию осуществляли только с помощью Зенапакса. По демографическим и клинико-лабораторным параметрам группы были идентичны. Полученные данные были подвергнуты статистической обработке методом малой выборки с использованием критерия Стьюдента. Проведенный анализ показал, что у больных, которым вводили Кемпас, продолжительность интервалов между введениями Зенапакса значительно увеличивалась (разница статистически достоверна). Следовательно: Кемпас потенцирует иммунодепрессивное действие Зенапакса.

Since a moment of introduction of Kampath in complex of immunosuppression in the department of kidney transplantation we decided to elucidate wether Kampath is capable to potentate the action of simultaneously administered Zenapax. To appreciate this as a test a length of intervals between Zenapax infusions was taken. Kampath was infused to 7 patients twice: first dose of drug was infused 17-21 days before transplantation. A second one - in the day of kidney transplantation, just the plasmapheresis was terminated. As a control group 9 patients to whom inductive immunosuppresion was realized with Zenapax only was used. Both groups were identical by demographic and laboratory-clinical parameters. Data were statistically treated with the use of Studant criterion. Executed analysis has demonstrated, that in patients with Kampath a length of intervals between infusions of Zenapax was greater than in patients without Zenapax (difference was statistically authentic). Therefore, Kampath exponentiate immunosuppressive activity of Zenapax.

пересадка почкииммунодепрессияиндукцияReferencesBurke J.R. jr, Pirsh J.D., Ramon E.L. et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358.Burke J.R. jr, Pirsh J.D., Ramon E.L. et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358.Chanraker A., Takada M., Nadeau K.C., Peach R., Tinley N., Sayegh M. CD28-B7 blockade in organ dysfunction secondary to cold ishemia/reperfusion injury. Kidney International 1997; 52: 1678-1684.Chanraker A., Takada M., Nadeau K.C., Peach R., Tinley N., Sayegh M. CD28-B7 blockade in organ dysfunction secondary to cold ishemia/reperfusion injury. Kidney International 1997; 52: 1678-1684.Ciancio G., Burke G.V., Suzart К. et al. Daclizumab induction, tacrolimus, mycophenalate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.Ciancio G., Burke G.V., Suzart К. et al. Daclizumab induction, tacrolimus, mycophenalate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.Coenen J.J., Koenen H.J., van Rijssen E. et al. CTLA-4 engagement and regulatory CD4+CD25+ T cells independently control CD8+-mediated responses under costimulation blockade. J Immunol 2006 May 1; 176 (9): 5240-5246.Coenen J.J., Koenen H.J., van Rijssen E. et al. CTLA-4 engagement and regulatory CD4+CD25+ T cells independently control CD8+-mediated responses under costimulation blockade. J Immunol 2006 May 1; 176 (9): 5240-5246.Firch J.D., Miller J., Deierhoi M.H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression, after cadaveric renal trsnsplantation. Transplantation 1997; 63: 977.Firch J.D., Miller J., Deierhoi M.H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression, after cadaveric renal trsnsplantation. Transplantation 1997; 63: 977.Goes N., Urmos J., Ramassar V., Halloran P.F. Ishemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1: granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59: 565-572.Goes N., Urmos J., Ramassar V., Halloran P.F. Ishemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1: granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59: 565-572.Harharan S., Johnson C.P., Bresnahan R.A. et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Ingl J Med 2000; 342: 605.Harharan S., Johnson C.P., Bresnahan R.A. et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Ingl J Med 2000; 342: 605.Kuypers D.R., Evenepoel P., Maes B. et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 75: 37.Kuypers D.R., Evenepoel P., Maes B. et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 75: 37.Larsen C.P., Ritchie S.C., Hendrix R., Linsley P.S., Hathcock K.S., Hodes R.J., Pearson T.C. Regulation of immunostimulatory function and costimulatorymolecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.Larsen C.P., Ritchie S.C., Hendrix R., Linsley P.S., Hathcock K.S., Hodes R.J., Pearson T.C. Regulation of immunostimulatory function and costimulatorymolecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.Nashan B., Light S., Hardie I.R. et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.Nashan B., Light S., Hardie I.R. et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.Ojo A.O., Meier-Krieshe H.U., Hanson J.A. et al. Mycophenolate mofetil reduces late renal allograft loss independent rejection. Transplantation 2000; 69: 2405.Ojo A.O., Meier-Krieshe H.U., Hanson J.A. et al. Mycophenolate mofetil reduces late renal allograft loss independent rejection. Transplantation 2000; 69: 2405.Perco P., Blaha P., Kainz A. et al. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int 2006 Feb; 19 (2): 146-157.Perco P., Blaha P., Kainz A. et al. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int 2006 Feb; 19 (2): 146-157.Shapiro R., Ellis D., Tan H.P. et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006 Jun; 148 (6): 813-818.Shapiro R., Ellis D., Tan H.P. et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006 Jun; 148 (6): 813-818.Takada M., Chandraker A., Nadeau K.C., Sayegh M.H., Tilney N.L. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997; 1; 100 (5): 1199-1203.Takada M., Chandraker A., Nadeau K.C., Sayegh M.H., Tilney N.L. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997; 1; 100 (5): 1199-1203.Tan H.P., Kaczorowski D.J., Basu A. et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6 (10): 2409-2417.Tan H.P., Kaczorowski D.J., Basu A. et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6 (10): 2409-2417.Thai N.L., Abu-Elmagd K., Khan A. et al. Pancreatic transplantation at the University of Pittsburgh. Clin Transpl 2004; 205-214.Thai N.L., Abu-Elmagd K., Khan A. et al. Pancreatic transplantation at the University of Pittsburgh. Clin Transpl 2004; 205-214.Tran H.T., Acharya M.K., McKay D.B. et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Amer Soc Nephrol 2000; 11: 1903.Tran H.T., Acharya M.K., McKay D.B. et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Amer Soc Nephrol 2000; 11: 1903.The Tricontinental Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996; 61: 1029.The Tricontinental Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996; 61: 1029.Vathsala A., Ona E.T., Tan S.Y. et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80 (6): 765-774.Vathsala A., Ona E.T., Tan S.Y. et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80 (6): 765-774.Vincenti F., Ramos E., Brattstrom C. et al. Multicenter trial exploring calcineurine inhibitors-avoidance in renal reansplantation. Transplantation 2001; 71: 1282.Vincenti F., Ramos E., Brattstrom C. et al. Multicenter trial exploring calcineurine inhibitors-avoidance in renal reansplantation. Transplantation 2001; 71: 1282.Watson C.J., Bradely J.A., Friend P.J. et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005; 5 (6): 1347-1538.Watson C.J., Bradely J.A., Friend P.J. et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005; 5 (6): 1347-1538.

The authors declare that there are no conflicts of interest present.